Ioannis Gounaris
Company: Merck KGaA
Job title: Vice President, Clinical Development
Seminars:
Chair’s Closing Remarks & End of Day One 5:45 pm
day: Day One
Panel Discussion: How Can We Holistically Prioritise Combination Strategies Across the DDR Landscape & Leverage These to Tackle PARP inhibitor resistance? 11:30 am
How can we effectively integrate combination strategies that target complementary DNA damage response (DDR) pathways, such as combining PARP inhibitors with emerging DDR modulators like USP1 inhibitors, to enhance therapeutic efficacy? What role do biomarkers, particularly those related to homologous recombination repair (HRR) deficiencies, play in guiding the selection of optimal combination therapies tailored to…Read more
day: Day One
Chair’s Opening Remarks 7:55 am
day: Day One